REMODULIN
Total Payments
$7.3M
Transactions
5,049
Doctors
1,577
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.1M | 1,278 | 414 |
| 2023 | $407,437 | 574 | 319 |
| 2022 | $484,172 | 548 | 287 |
| 2021 | $398,609 | 628 | 323 |
| 2020 | $292,298 | 215 | 76 |
| 2019 | $889,847 | 1,066 | 365 |
| 2018 | $1.1M | 567 | 330 |
| 2017 | $491,726 | 173 | 95 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.1M | 898 | 84.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $764,749 | 343 | 10.5% |
| Consulting Fee | $167,210 | 76 | 2.3% |
| Food and Beverage | $123,453 | 3,111 | 1.7% |
| Travel and Lodging | $78,819 | 392 | 1.1% |
| Education | $3,871 | 228 | 0.1% |
| Grant | $2,500 | 1 | 0.0% |
Payments by Type
Research
$6.1M
898 transactions
General
$1.1M
4,151 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) | United Therapeutics Corporation | $3.0M | 2 |
| INTRAVENOUS REMODULIN TREPROSTINIL AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN A RANDOMIZED PLACEBO-CONTROLLED SAFETY AND EFFICACY STUDY | United Therapeutics Corporation | $869,136 | 0 |
| REMODULIN AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN | United Therapeutics Corporation | $486,069 | 0 |
| INTRAVENOUS REMODULIN (TREPROSTINIL) AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN: A RANDOMIZED PLACEBO-CONTROLLED SAFETY AND EFFICACY STUDY | United Therapeutics Corporation | $379,460 | 0 |
| EVALUATION OF THE PRELIMINARY SAFETY AND EFFICACY OF TREPROSTINIL (REMODULIN) IN REDUCING ISCHEMIA-REPERFUSION INJURY DURING DE NOVA ADULT KIDNEY TRANSPLANTATION. | United Therapeutics Corporation | $257,999 | 0 |
| HUMAN MSC EXOSOME THERAPY FOR BPD INJURY IN THE PRETERM LAMB PRE-CLINICAL MODEL | United Therapeutics Corporation | $200,000 | 0 |
| ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | United Therapeutics Corporation | $172,411 | 0 |
| REMODULIN IN PH ASSOCIATED WITH HFPEF | United Therapeutics Corporation | $156,595 | 0 |
| Unspecified Research Projects | United Therapeutics Corporation | $135,101 | 1 |
| A Phase I and II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation | United Therapeutics Corporation | $127,240 | 0 |
| EXPEDITE: A 16-WEEK MULTICENTER OPEN-LABEL STUDY OF REMODULIN INDUCTION FOLLOWED BY ORENITRAM OPTIMIZATION IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $71,886 | 0 |
| Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation | United Therapeutics Corporation | $57,531 | 0 |
| TREPROSTINIL FOR BPD | United Therapeutics Corporation | $31,864 | 0 |
| EXPEDITE A 16-WEEK MULTICENTER OPEN-LABEL STUDY OF REMODULIN INDUCTION FOLLOWED BY ORENITRAM OPTIMIZATION IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $31,539 | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) | United Therapeutics Corporation | $26,346 | 0 |
| Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study | United Therapeutics Corporation | $16,322 | 0 |
| A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And Function) | United Therapeutics Corporation | $15,100 | 1 |
| AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301 | United Therapeutics Corporation | $13,926 | 0 |
| UNSPECIFIED RESEARCH PROJECTS | United Therapeutics Corporation | $12,750 | 1 |
| Y-SITE COMPATIBILITY OF TREPROSTINIL WITH DOPAMINE AND HEPARIN | United Therapeutics Corporation | $6,280 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $7.3M
- Total Doctors 1,577
- Transactions 5,049
About REMODULIN
REMODULIN is a drug associated with $7.3M in payments to 1,577 healthcare providers, recorded across 5,049 transactions in the CMS Open Payments database. The primary manufacturer is United Therapeutics Corporation.
Payment data is available from 2017 to 2024. In 2024, $3.1M was paid across 1,278 transactions to 414 doctors.
The most common payment nature for REMODULIN is "Unspecified" ($6.1M, 84.3% of total).
REMODULIN is associated with 20 research studies, including "A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION)" ($3.0M).